Scholarlink

Purpose <p><i>Mimosa pudica</i> is a medicinal plant conventionally used to cure various ailments, including diabetes and is a model for synthesizing new drug derivatives. This work evaluates the glucose utilization potential of Zinc oxide nanoparticles (ZnONPs) derived from the ethanol root extract of <i>M. pudica</i> in 3T3-L1 adipocyte cells.</p> Methods <p>Molecular modeling tools were used to predict the potential antidiabetic compounds from <i>M. pudica</i>. ZnONPs were biosynthesized using <i>M. pudica</i> extract, and their physicochemical properties were characterized using UV-visible, FTIR, XRD, DLS, XPS, and FESEM techniques. The in vitro cellular viability of synthesized ZnONPs and glucose utilization efficiency were examined in 3T3-L1 adipocytes.</p> Results <p>Using GC-MS and LC-MS analyses, 27 novel bioactive compounds were identified from <i>M. pudica</i> root extract. For the efficient glucose utilization in 3T3-L1 adipocytes, Dipeptidyl-peptidase 4 (DPP-4) inhibition plays a pivotal role, as three of the top binding-scored molecules from <i>M. pudica</i> were identified via molecular docking and dynamics simulation studies. 500&#xa0;µg of ZnONPs exhibited 73.47 ± 1.59% cellular viability. Further, the in vitro glucose utilization efficiency of ZnONPs was evidenced in 3T3-L1 adipocytes, which displayed concentration-dependent glucose utilization. The effect of ZnONPs (30&#xa0;µg) on glucose uptake was higher than that of 10&#xa0;µg of metformin. Bioactive compounds from <i>M. pudica</i> extract might inactivate the DPP-4 enzyme activity and improve insulin release from the pancreas, lowering blood glucose levels via GLUT4 activation.</p> Conclusion <p>The findings imply that <i>M. pudica</i>-mediated synthesized ZnONPs might be a plant-based novel oral nanoformulation for managing diabetes mellitus (DM).</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mimosa pudica Linn. Root Extract-Mediated Synthesis of Zinc Oxide Nanoparticles: a Study of Glucose Uptake Efficiency on 3T3-L1 Adipocytes

  • 期刊论文

  • 发表日期：

    2025年8月9日

查看全文
  • Chandrasekar Palanichamy,
  • Pavadai Parasuraman,
  • Panneerselvam Theivendren,
  • Murugesan Sankaranarayanan,
  • Madasamy Sundar,
  • Selvaraj Kunjiappan

摘要

Purpose

Mimosa pudica is a medicinal plant conventionally used to cure various ailments, including diabetes and is a model for synthesizing new drug derivatives. This work evaluates the glucose utilization potential of Zinc oxide nanoparticles (ZnONPs) derived from the ethanol root extract of M. pudica in 3T3-L1 adipocyte cells.

Methods

Molecular modeling tools were used to predict the potential antidiabetic compounds from M. pudica. ZnONPs were biosynthesized using M. pudica extract, and their physicochemical properties were characterized using UV-visible, FTIR, XRD, DLS, XPS, and FESEM techniques. The in vitro cellular viability of synthesized ZnONPs and glucose utilization efficiency were examined in 3T3-L1 adipocytes.

Results

Using GC-MS and LC-MS analyses, 27 novel bioactive compounds were identified from M. pudica root extract. For the efficient glucose utilization in 3T3-L1 adipocytes, Dipeptidyl-peptidase 4 (DPP-4) inhibition plays a pivotal role, as three of the top binding-scored molecules from M. pudica were identified via molecular docking and dynamics simulation studies. 500 µg of ZnONPs exhibited 73.47 ± 1.59% cellular viability. Further, the in vitro glucose utilization efficiency of ZnONPs was evidenced in 3T3-L1 adipocytes, which displayed concentration-dependent glucose utilization. The effect of ZnONPs (30 µg) on glucose uptake was higher than that of 10 µg of metformin. Bioactive compounds from M. pudica extract might inactivate the DPP-4 enzyme activity and improve insulin release from the pancreas, lowering blood glucose levels via GLUT4 activation.

Conclusion

The findings imply that M. pudica-mediated synthesized ZnONPs might be a plant-based novel oral nanoformulation for managing diabetes mellitus (DM).

Graphical Abstract